Inhibitor formation is the single most important complication of clotting factor concentrate usage, especially for patients with severe hemophilia A. Based on the total body of current knowledge and emerging data available at this time, any FVIII…
Inhibitor development is the single most important complication of clotting factor concentrate usage, especially for patients with severe hemophilia A. Based on the total body of current knowledge and emerging data available at this time, any Factor…
MASAC applauds the willingness of the payer community to work with NHF to insure that patients achieve access to the full spectrum of essential services offered through the comprehensive care setting of a Hemophilia Treatment Center (HTC).
MASAC…
Prophylaxis (regular administration of Factor VIII or Factor IX concentrate to prevent bleeds) is considered optimal therapy for patients with severe hemophilia. Patients with hemophilia who develop inhibitory antibodies (inhibitors) to factor VIII…
Replaces: 221
There has been considerable discussion in the hemophilia community regarding the optimal protocol for the administration of vaccines to individuals with bleeding disorders. Speculation that vaccines may induce the development of…
Revisions: 98
Indications and Safety Considerations
Individuals with hemophilia who have been treated with plasma-derived clotting factor concentrates are at risk for infection with hepatitis B and C. In this group, over 80%…
Revisions: 169; 106
The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on April 13, 2014, and adopted by the NHF Board of Directors on May 6, 2014.
Recombinant clotting factor concentrates differ…
The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on April 13, 2014, and adopted by the NHF Board of Directors on June 5, 2014.
Background
Patients with hemophilia and other bleeding disorders…
The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on April 13, 2014, and adopted by the NHF Board of Directors on June 5, 2014.
There is wide variability of factor activity level resultsdepending…
Revisions: 94
The National Hemophilia Foundation is a vigilant advocate for the safety of the nation's blood and plasma products and derivatives. MASAC supports the maintenance of the Patient Notification System (PNS), established by the PPTA,…